Summary:
Molbio Diagnostics IPO subscription rose to 3.11x by the end of Day 2, with all investor categories oversubscribed. NII led demand at 5.21x, followed by employee investors at 4.78x and retail investors at 3.18x, while QIB subscription reached 1.39x. The ₹939.70 crore IPO closes on August 12, with listing scheduled for August 17. Strong demand reflects investor interest in Molbio's diagnostics portfolio, Truenat platform and global patent presence.
Molbio Diagnostics' IPO is now in its second day of bidding, August 11, 2026. The company develops and manufactures diagnostic testing devices used to detect infectious and other diseases, with its flagship Truenat platform, a portable testing machine that delivers results in about an hour. As of March 31, 2026, its portfolio covered 30 diseases through 43 assays, including tests for tuberculosis, COVID-19, HIV, hepatitis B and C, and HPV. The company's TB test is among the rapid molecular diagnostic tests recommended by the World Health Organization for initial detection of TB and rifampicin resistance, and its Truenat technology holds patent protection in more than 100 countries.
This is a ₹939.70 crore IPO, made up of a ₹200 crore fresh issue and an offer for sale of ₹739.70 crore. The fresh issue proceeds are earmarked for capital expenditure toward setting up infrastructure for a research and development facility and Centre of Excellence, to be operated by wholly owned subsidiary Bigtec, among other purposes, while the OFS portion goes to existing shareholders selling part of their stake.
Price band is ₹768 to ₹807 per share. Lot size is 18 shares, so retail investors need ₹14,526 to apply at the upper end. The issue closes today, August 12, and listing is expected August 17 on both BSE and NSE.
Molbio Diagnostics IPO - Day 2 Subscription Status
Day 1 closed with the issue subscribed 0.67 times overall, building steadily through the session from a slow morning start. Demand has strengthened further on Day 2, pushing the issue past full subscription.
Category-wise Breakdown on Day 2
| Category | Subscription (Day 2, as of 5:00 PM) |
| Qualified Institutional Buyers (QIB) | 1.39x |
| Non-Institutional Investors (NII) | 5.21x |
| — Big NII (bNII, >₹10L) | 4.31x |
| — Small NII (sNII, ₹2–10L) | 7.01x |
| Retail Individual Investors (RII) | 3.18x |
| Employee | 4.78x |
| Overall | 3.11x |
Figures as of 5:00 PM, August 11, 2026 (Day 2, consolidated bid details), per NSE data. The issue received bids for 2.53 crore shares against 81.58 lakh shares on offer.
What Day 2 Numbers Indicate
NII has led the charge on Day 2, coming in at 5.21x, with small HNIs (7.01x) well ahead of big HNIs (4.31x). This kind of strong non-institutional response this early is a good signal of investor conviction in the listing.
Retail has also moved comfortably into oversubscribed territory at 3.18x, and the employee quota is running hotter still at 4.78x. QIB, at 1.39x, has crossed full subscription too, a reasonable early signal of institutional interest, though QIBs typically place the bulk of their bids in the final hours of the closing day, so this figure has room to climb further.
Overall subscription at 3.11x by Day 2's close confirms the issue is comfortably oversubscribed, with every single category now past the 1x mark. Given the company's distinctive position in India's diagnostics space, backed by WHO-recommended TB testing technology and patents across more than 100 countries, alongside a strong anchor book featuring Goldman Sachs, BlackRock, and IFC, this broad-based demand across every category tracks with a solid underlying business case.
Molbio Diagnostics IPO - Allotment and Listing Date
| Event | Date |
| Basis of Allotment | August 13, 2026 |
| Refund Initiation | August 14, 2026 |
| Shares Credited to Demat | August 13–14, 2026 |
| Listing Date | August 17, 2026 |
Should You Apply for Molbio Diagnostics IPO?
A few things worth weighing before you decide:
- It's a mix of fresh issue and offer for sale, with the ₹200 crore fresh issue going toward R&D infrastructure and a Centre of Excellence under subsidiary Bigtec, while the larger ₹739.70 crore OFS portion goes to existing shareholders exiting part of their stake.
- FY26 revenue rose 42% year-on-year, though profit after tax grew a more modest 18%, suggesting some margin pressure even as the top line scaled up strongly.
- Molbio holds a distinctive position in India's diagnostics space, with WHO-recommended TB testing technology and patent protection across more than 100 countries, operating in a sector that's a cornerstone of India's expanding healthcare industry.
- Every category, QIB, NII, retail, and employee, is now comfortably oversubscribed as of Day 2's close, a broad-based signal of investor confidence across the board.
- With demand already running well ahead of the shares on offer in every category, allotment is very likely to be decided by lottery for retail and NII applicants.
This is informational content, not investment advice. Weigh your own risk appetite before applying.
How to Apply for Molbio Diagnostics IPO
You can apply through any of these routes:
- ASBA via net banking – log into your bank's net banking, go to the IPO section, select Molbio Diagnostics, enter quantity and bid price, then authorise.
- UPI via broker app – open your broker app, find the IPO under current issues, enter your UPI ID and bid details, then approve the mandate on your UPI app.
- Physical ASBA form – submit through your bank branch if you prefer the offline route.
Since this is the closing day, get your application in well before the cut-off this evening. Bid in multiples of the 18-share lot, and apply at the cut-off price to keep your allotment chances intact.
Molbio Diagnostics IPO Important Dates
| Event | Date |
| IPO Open Date | August 10, 2026 |
| IPO Close Date | August 12, 2026 |
| Basis of Allotment | August 13, 2026 |
| Refunds Initiated | August 14, 2026 |
| Demat Credit | August 13–14, 2026 |
| Listing Date | August 17, 2026 |
How to Check Molbio Diagnostics IPO Subscription Status
How to check Molbio Diagnostics IPO Subscription Status on NSE website
- Go to the NSE India website and open the "Live IPO Bidding" section.
- Select Molbio Diagnostics Limited from the dropdown.
- You'll see category-wise bid numbers, updated through the trading day.
How to check Molbio Diagnostics IPO Subscription Status on BSE website
- Visit the BSE India IPO page.
- Search for Molbio Diagnostics under active issues.
- Click on it to view live bid quantity against shares reserved, split by category.
How to check Molbio Diagnostics IPO Subscription Status on Ventura?
Log into your Ventura account, go to the IPO section, and select Molbio Diagnostics from the list of live issues. You'll find the live subscription numbers along with your own application status if you've already applied.
IPO Subscription History
Previous Day Subscription
Day 1 closed with the issue subscribed 0.67 times overall, building through the session from a slow morning start.
Final Subscription Figures
Final numbers will only be available after the issue closes today, August 12, 2026. Check back once bidding wraps up for the complete category-wise final tally.
Conclusion
Molbio Diagnostics' IPO has moved comfortably past full subscription on Day 2, closing at 3.11x overall with every category, QIB (1.39x), NII (5.21x), retail (3.18x), and employees (4.78x), now oversubscribed. Backed by a strong anchor book featuring Goldman Sachs, BlackRock, and IFC, and a distinctive position in India's diagnostics industry, this broad-based demand is a good signal heading into the final hours of bidding today.
